Onsdag 28 Oktober | 18:57:10 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Alzecure - Progress across the board

2023-03-30 14:10:00

Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and upcoming catalysts. We continue to see an interesting neurology platform case with an eventful future ahead. We believe that the current valuation of the company is undemanding and presents a favorable opportunity to enter at these levels.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/